Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FAST trial clears febuxostat of increased mortality in gout

Publish date:: November 10, 2020

Key clinical point: Febuxostat demonstrated noninferiority to allopurinol for mortality.

Major finding: Unlike the CARES trial in the United States, the FAST trial suggested no increased mortality risk associated with febuxostat.

Study details: Multicenter, prospective, randomized study of 6,128 people.

Disclosures: Menarini, Ipsen, and Teijin Pharma funded the study. The University of Dundee receives research funds from Menarini. Dr. MacDonald disclosed that he received speaker or consultant fees from Menarini.

Citation:

MacDonald T et al. Arthritis Rheumatol. 2020;72(suppl 10). ACR 2020, Abstract L08.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Sac/val heart failure benefit extends to diabetes patients,

Study results support screening rosacea patients for cardiometabolic disease,

Obesity, hypoxia predict severity in children with COVID-19,

Obesity phenotyping matches patients with more effective interventions,

Must Reads in Acute Coronary Syndromes

Stenotic lesion outcomes better if fractional flow reserve guides PCI,

Methotrexate and hydroxychloroquine split on cardiovascular outcomes in RA,

FAST trial clears febuxostat of increased mortality in gout,

Cardiogenic shock rate soars in COVID-positive ACS,

MitraClip effective for post-MI acute mitral regurgitation with cardiogenic shock,